Return to PJ Online Home Page
The Pharmaceutical Journal Vol 265 No 7116 p480
September 30, 2000 Letters

PPA

Clarification

From Mr M. King

SIR,—You published two items last week (p435 Item 1 & Item 2), both of which referred to the Prescription Pricing Authority. The first of these, entitled “Under-cover pharmacy checks planned”, refers to the apparent intention of the PPA to send under-cover investigators to community pharmacies to make sure that checks on patients’ entitlements are properly carried out. This item also refers to the “PPA’s directorate of counter fraud services”. Neither statement is true.
The Directorate of Counter Fraud Services (DCFS) is a part of the NHS Executive rather than the PPA. It is quite separate from this authority. The PPA has no plans to carry out exercises in pharmacies of the kind described. The PPA has a compliance unit (previously the fraud investigation unit) and its primary function is to undertake checks on patient claims to exemption from prescription charges, following up unconfirmed cases with the patient concerned. Although the compliance unit does support the DCFS by providing information to assist its enquiries, we do not investigate fraud ourselves.
A similar confusion arises from the second item, “PPA fraud clampdown shows results”. Whereas much of the text is accurate, it appears out of context. The basic position is that the PPA’s compliance unit does not investigate fraud. That is the responsibility of the DCFS. However, we do take civil action to recover debt. This arises in cases where we have carried out checks on patient claims to exemption, found these to be incorrect and the patient declines to pay. These actions take place in county courts but are not prosecutions for fraud. The “fraud incentive scheme” to which you referred is described in a report in the September issue of Impact by its correct title, the Pharmacy Reward scheme. It has resulted in the figures quoted.
I believe that it is important that the equally significant, but separate, responsibilities of the DCFS and the PPA are understood.

 

Michael King
Director of Planning and Corporate Affairs,
Prescription Pricing Authority